Therapeutic angiogenesis for ischemic syndromes.

Area of Science:

• Cardiovascular Biology
• Gene Therapy
• Vascular Biology

Background:

• Atherosclerosis is a leading cause of death, with limited treatment options for patients unsuitable for angioplasty or surgery.
• Enhancing collateral circulation is crucial for improving blood flow to ischemic tissues.

Purpose of the Study:

• To evaluate the efficacy of adenoviral vectors for gene transfer of vascular endothelial growth factor (VEGF).
• To assess VEGF-mediated angiogenesis in human vascular cells in vitro and in vivo.

Main Methods:

• Adenoviral vectors encoding lacZ and VEGF (rAdlacZ, rAdVEGF) were used to infect human saphenous vein endothelial and smooth muscle cells.
• VEGF expression and biological activity were analyzed using Western blot and proliferation assays.
• In vivo gene transfer feasibility was assessed via direct femoral artery injection of rAdlacZ in rats.

Main Results:

• Adenoviral vector-mediated VEGF expression was confirmed in infected human vascular cells.
• VEGF significantly increased endothelial cell proliferation by threefold compared to controls.
• Successful in vivo gene transfer of lacZ to arterial wall cells was demonstrated in rats.

Conclusions:

• Adenoviral vectors provide efficient gene delivery both in vitro and in vivo.
• VEGF overexpression via gene therapy promotes endothelial cell proliferation, a key step in angiogenesis.
• This strategy holds promise for developing less invasive treatments for arterial obstructive diseases.